Trial Profile

A multicenter, open-label study to determine the efficacy and safety of lucerastat oral therapy in Japanese subjects with Fabry disease

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 27 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lucerastat (Primary)
Indications Fabry's disease
Focus Registrational; Therapeutic Use
Sponsors Idorsia Pharmaceuticals

Most Recent Events

26 Apr 2022 Status changed from active, no longer recruiting to completed.
16 Dec 2021 New trial record
13 Dec 2021 According to an Idorsia Pharmaceuticals media release, results of the study are currently in preparation for scientific disclosure in a peer-reviewed publication.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com